Neurocrine Biosciences, Inc. (LON:0K6R)
London · Delayed Price · Currency is GBP · Price in USD 141.50
-2.54 (-1.76%)
Dec 30, 2025, 5:00 PM BST
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,800 employees as of December 31, 2024. The number of employees increased by 400 or 28.57% compared to the previous year.
Employees
1,800
Change (1Y)
400
Growth (1Y)
28.57%
Revenue / Employee
1.11M GBP
Profits / Employee
176.89K GBP
Market Cap
10.43B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Dec 31, 2020 | 845 | 145 | 20.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Convatec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,811 |
Neurocrine Biosciences News
- 7 days ago - Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage - Benzinga
- 7 days ago - Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage - Benzinga
- 7 days ago - Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq
- 8 days ago - Neurocrine Biosciences (NBIX) Faces Setback with Ingrezza Trial - GuruFocus
- 8 days ago - Neurocrine's movement disorder treatment fails late-stage trial - Reuters
- 8 days ago - Neurocrine Biosciences (NBIX) Phase 3 Trial Results Disappoint in DCP Treatment - GuruFocus
- 8 days ago - Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PRNewsWire
- 13 days ago - NBIX: HC Wainwright & Co. Raises Price Target to $198, Maintains Buy Rating | NBIX Stock News - GuruFocus